Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 575

1.

Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy.

Wyatt CM, Drüeke TB.

Kidney Int. 2019 Aug 23. pii: S0085-2538(19)30687-8. doi: 10.1016/j.kint.2019.06.011. [Epub ahead of print] No abstract available.

PMID:
31451300
2.

Strategies for Phosphate Control in Patients With CKD.

Barreto FC, Barreto DV, Massy ZA, Drüeke TB.

Kidney Int Rep. 2019 Jun 20;4(8):1043-1056. doi: 10.1016/j.ekir.2019.06.002. eCollection 2019 Aug. Review.

3.

Blood pressure measurement in mice: tail-cuff or telemetry?

Drüeke TB, Devuyst O.

Kidney Int. 2019 Jul;96(1):36. doi: 10.1016/j.kint.2019.01.018. No abstract available.

PMID:
31229048
4.

Erratum.

Drüeke TB, Massy ZA.

Nephrol Dial Transplant. 2019 May 18. pii: gfz112. doi: 10.1093/ndt/gfz112. [Epub ahead of print] No abstract available.

PMID:
31102523
5.

The Bone after Kidney Transplantation.

Drüeke TB, Evenepoel P.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):795-797. doi: 10.2215/CJN.04940419. Epub 2019 May 14. No abstract available.

PMID:
31088852
6.

Vascular calcification - any place left for nicotinamide?

Drüeke TB, Massy ZA.

Nephrol Dial Transplant. 2019 Apr 9. pii: gfz057. doi: 10.1093/ndt/gfz057. [Epub ahead of print] No abstract available.

PMID:
31071218
7.

Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?

Lenglet A, Fabresse N, Taupin M, Gomila C, Liabeuf S, Kamel S, Alvarez JC, Drueke TB, Massy ZA.

Drugs. 2019 Jun;79(8):855-862. doi: 10.1007/s40265-019-01118-9.

PMID:
31062264
8.

Erythropoiesis-Stimulating Agents and Mortality.

Drüeke TB, Massy ZA.

J Am Soc Nephrol. 2019 Jun;30(6):907-908. doi: 10.1681/ASN.2019030266. Epub 2019 Apr 23. No abstract available.

PMID:
31015256
9.

Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease.

Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, Cavalier E, Cohen-Solal M, Covic A, Drüeke TB, Hindié E, Evenepoel P, Frazão J, Goldsmith D, Kazama JJ, Cozzolino M, Massy ZA; ERA-EDTA CKD-MBD Working Group.

Clin Kidney J. 2018 Jul 20;12(2):269-280. doi: 10.1093/ckj/sfy061. eCollection 2019 Apr.

10.

High-dose IV iron for anemia correction in chronic kidney disease.

Wyatt CM, Drueke TB.

Kidney Int. 2019 Apr;95(4):727-730. doi: 10.1016/j.kint.2019.01.013. No abstract available. Erratum in: Kidney Int. 2019 Jun;95(6):1518.

PMID:
30904057
11.

Vitamin D deficiency and chronic kidney disease risk: cause or merely association?

McCarron DA, Drueke TB.

Am J Clin Nutr. 2018 Dec 1;108(6):1164-1165. doi: 10.1093/ajcn/nqy299. No abstract available.

PMID:
30541091
12.

Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients.

Fouque D, Roth H, Darné B, Bouchet JL, Daugas E, Drüeke TB, Hannedouche T, Jean G, London GM.

Clin Kidney J. 2018 Oct;11(5):710-719. doi: 10.1093/ckj/sfy015. Epub 2018 Mar 15.

13.

Relative prognostic impact of nutrition, anaemia, bone metabolism and cardiovascular comorbidities in elderly haemodialysis patients.

Villain C, Ecochard R, Bouchet JL, Daugas E, Drueke TB, Hannedouche T, Jean G, London G, Roth H, Fouque D.

Nephrol Dial Transplant. 2019 May 1;34(5):848-858. doi: 10.1093/ndt/gfy272.

PMID:
30202988
14.

Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.

Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P.

Kidney Int. 2018 Jun;93(6):1475-1482. doi: 10.1016/j.kint.2017.12.014. Epub 2018 Mar 7.

PMID:
29525393
15.

Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study.

Fouque D, Roth H, Darné B, Jean-Bouchet L, Daugas E, Drüeke TB, Hannedouche T, Jean G, London GM; French Phosphorus and Calcium Observatory.

Clin Kidney J. 2018 Feb;11(1):73-79. doi: 10.1093/ckj/sfx101. Epub 2017 Sep 23.

16.

Lowering Expectations with Niacin Treatment for CKD-MBD.

Drüeke TB, Massy ZA.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):6-8. doi: 10.2215/CJN.12021017. Epub 2017 Dec 5. No abstract available.

17.

[Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature].

Seidowsky A, Dupuis E, Drueke T, Dard S, Massy ZA, Canaud B.

Nephrol Ther. 2018 Feb;14(1):35-41. doi: 10.1016/j.nephro.2017.04.002. Epub 2017 Nov 23. Review. French.

PMID:
29174672
18.

Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease.

Kaboré J, Metzger M, Helmer C, Berr C, Tzourio C, Drueke TB, Massy ZA, Stengel B.

Kidney Int Rep. 2016 Oct 31;2(2):180-191. doi: 10.1016/j.ekir.2016.10.006. eCollection 2017 Mar.

19.

Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study.

Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L.

Clin Kidney J. 2017 Aug;10(4):578. doi: 10.1093/ckj/sfx068. Epub 2017 Jul 9.

20.

[Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].

Jean G, Daugas É, Roth H, Drueke T, Bouchet JL, Hannedouche T, London G, Fouque D.

Nephrol Ther. 2017 Nov;13(6):470-478. doi: 10.1016/j.nephro.2017.02.009. Epub 2017 Aug 23. French.

PMID:
28843391
21.

Vascular calcification in chronic kidney disease: here to stay?

Wyatt CM, Drueke TB.

Kidney Int. 2017 Aug;92(2):276-278. doi: 10.1016/j.kint.2017.05.019.

PMID:
28709592
22.

Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study.

Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L.

Clin Kidney J. 2017 Feb;10(1):30-37. doi: 10.1093/ckj/sfw060. Epub 2016 Jul 4. Retraction in: Clin Kidney J. 2017 Aug;10 (4):578.

23.

Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Massy Z, Drueke T.

J Nephrol. 2017 Oct;30(5):629-634. doi: 10.1007/s40620-017-0397-7. Epub 2017 Apr 12. Review.

PMID:
28405928
24.

The Authors Reply.

Hannedouche T, Roth H, Krummel T, Drüeke T, Fouque D.

Kidney Int. 2017 Mar;91(3):756. doi: 10.1016/j.kint.2016.11.014. No abstract available.

PMID:
28202173
25.

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM.

JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468.

26.

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM.

JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.

27.

HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.

Wyatt CM, Drüeke TB.

Kidney Int. 2016 Nov;90(5):923-925. doi: 10.1016/j.kint.2016.08.016.

PMID:
27742192
28.

Multiphasic effects of blood pressure on survival in hemodialysis patients.

Hannedouche T, Roth H, Krummel T, London GM, Jean G, Bouchet JL, Drüeke TB, Fouque D; French Observatory.

Kidney Int. 2016 Sep;90(3):674-84. doi: 10.1016/j.kint.2016.05.025.

29.

Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?

Massy ZA, Drueke TB.

Kidney Int. 2016 Jun;89(6):1180-2. doi: 10.1016/j.kint.2016.02.006.

PMID:
27181771
30.

Development and validation of cardiovascular risk scores for haemodialysis patients.

Anker SD, Gillespie IA, Eckardt KU, Kronenberg F, Richards S, Drueke TB, Stenvinkel P, Pisoni RL, Robinson BM, Marcelli D, Froissart M, Floege J; On behalf the ARO Steering Committee (collaborators).

Int J Cardiol. 2016 Aug 1;216:68-77. doi: 10.1016/j.ijcard.2016.04.151. Epub 2016 Apr 20.

PMID:
27140339
31.

Higher hemoglobin levels and quality of life in patients with advanced chronic kidney disease: no longer a moving target?

Wyatt CM, Drueke TB.

Kidney Int. 2016 May;89(5):971-973. doi: 10.1016/j.kint.2016.03.001.

PMID:
27083270
32.

Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.

Merle E, Roth H, London GM, Jean G, Hannedouche T, Bouchet JL, Drüeke T, Fouque D, Daugas E; French Calcium and Phosphate Observatory.

Kidney Int. 2016 Mar;89(3):666-74. doi: 10.1016/j.kint.2015.12.001. Epub 2016 Feb 2.

33.

Role of proton receptor OGR1 in bone response to metabolic acidosis?

Jorgetti V, Drüeke TB, Ott SM.

Kidney Int. 2016 Mar;89(3):529-31. doi: 10.1016/j.kint.2015.12.031.

PMID:
26880446
34.

[Changes in mineral and bone disorder management in a French cohort of hemodialysis patients between 2008 and 2012: The National Bone and Mineral Metabolism observatory (Photo-Graphe 2 and 3)].

Pelletier S, Roth H, Bouchet JL, Drueke TB, Hannedouche T, Jean G, London G, Fouque D; les investigateurs de l’observatoire Photo-Graphe 3.

Nephrol Ther. 2016 Jun;12(3):171-7. doi: 10.1016/j.nephro.2015.11.005. Epub 2016 Jan 25. French.

PMID:
26822333
35.

Changing bone patterns with progression of chronic kidney disease.

Drüeke TB, Massy ZA.

Kidney Int. 2016 Feb;89(2):289-302. doi: 10.1016/j.kint.2015.12.004. Review.

PMID:
26806832
36.

Salt and health: time to revisit the recommendations.

Drüeke TB.

Kidney Int. 2016 Feb;89(2):259-60. doi: 10.1016/j.kint.2015.12.009.

PMID:
26806824
37.

Parathyroidectomy or Calcimimetic to Treat Hypercalcemia after Kidney Transplantation?

Fukagawa M, Drüeke TB.

J Am Soc Nephrol. 2016 Aug;27(8):2221-4. doi: 10.1681/ASN.2015121349. Epub 2016 Jan 15. No abstract available.

38.

Fibroblast growth factor receptor 4: the missing link between chronic kidney disease and FGF23-induced left ventricular hypertrophy?

Wyatt CM, Drüeke TB.

Kidney Int. 2016 Jan;89(1):7-9. doi: 10.1016/j.kint.2015.11.012.

PMID:
26759036
39.

Hemodiafiltration Versus Hemodialysis and Survival in Patients With ESRD: The French Renal Epidemiology and Information Network (REIN) Registry.

Mercadal L, Franck JE, Metzger M, Urena Torres P, de Cornelissen F, Edet S, Béchade C, Vigneau C, Drüeke T, Jacquelinet C, Stengel B; REIN Registry.

Am J Kidney Dis. 2016 Aug;68(2):247-255. doi: 10.1053/j.ajkd.2015.11.016. Epub 2015 Dec 25.

PMID:
26724836
40.

Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.

de Francisco AL, Gillespie IA, Gioni I, Floege J, Kronenberg F, Marcelli D, Wheeler DC, Froissart M, Drueke TB; ARO Steering Committee Cllaborators.

Nefrologia. 2016;36(2):164-75. doi: 10.1016/j.nefro.2015.10.006. Epub 2015 Dec 3.

41.

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539-46. doi: 10.2215/CJN.06370615. Epub 2015 Nov 27. Review.

42.

Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients.

Stenvinkel P, Gillespie IA, Tunks J, Addison J, Kronenberg F, Drueke TB, Marcelli D, Schernthaner G, Eckardt KU, Floege J, Froissart M, Anker SD; ARO Steering Committee.

J Am Soc Nephrol. 2016 May;27(5):1479-86. doi: 10.1681/ASN.2015030252. Epub 2015 Nov 13.

43.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

44.

Oral or intravenous iron for anemia correction in chronic kidney disease?

Drüeke TB, Massy ZA.

Kidney Int. 2015 Oct;88(4):673-5. doi: 10.1038/ki.2015.189.

PMID:
26422625
45.

Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120.

Six I, Gross P, Rémond MC, Chillon JM, Poirot S, Drueke TB, Massy ZA.

Atherosclerosis. 2015 Nov;243(1):248-56. doi: 10.1016/j.atherosclerosis.2015.09.019. Epub 2015 Sep 15.

PMID:
26408929
46.

β2 microglobulin amyloidosis: an update 30 years later.

Jadoul M, Drüeke TB.

Nephrol Dial Transplant. 2016 Apr;31(4):507-9. doi: 10.1093/ndt/gfv318. Epub 2015 Sep 1. No abstract available.

PMID:
26333542
47.

Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.

Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, D'Haese PC, Drüeke TB, Du H, Manley T, Rojas E, Moe SM.

Am J Kidney Dis. 2016 Apr;67(4):559-66. doi: 10.1053/j.ajkd.2015.06.023. Epub 2015 Aug 25.

PMID:
26321176
48.

Peritoneal delivery of sodium pyrophosphate blocks the progression of pre-existing vascular calcification in uremic apolipoprotein-E knockout mice.

de Oliveira RB, Louvet L, Riser BL, Barreto FC, Benchitrit J, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Massy ZA.

Calcif Tissue Int. 2015 Aug;97(2):179-92. doi: 10.1007/s00223-015-0020-7. Epub 2015 Jun 19.

PMID:
26087714
49.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
50.

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM.

J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4.

PMID:
26040438

Supplemental Content

Loading ...
Support Center